Startups
2013
MANRESANA DE MICOBACTERIOLOGIA SL (MANREMYC)Nyaditum resae ® (NR) is the product able to induce the balanced immune response that diminish the risk of acquiring TB
Address
Carrer d'Urgell 26, 08241 Manresa, Spain
Social Media

Finance Data

DateInvestorsAmountStage 
Jul 2019235.358 €Pre-Seed

Financial Overview

No revenue recorded yet

CERCA ownership

Badalona, Spain

1995

IGTP

Status & Deeptech areas

Company Status & Company Deeptech Areas

Current company status

Current company status

DeepTech Area

DeepTech Area

Spinoff information

Company Description

Manremyc, a company with a unique and revolutionary product: Nyaditum resae® (NR), based on the most updated technology and a solid scientific background.

We are a Company with the mission to eradicate tuberculosis (TB) by reducing its risk of development with a unique and revolutionary product (Nyaditum resae® (NR)) based on the most updated technology and a solid scientific background.
Manremyc was founded and is actually supported by the Experimental Tuberculosis Unit, a scientific team leader of TB research in Europe

Product description

Nyaditum resae® is designed to face a major humankind problem, which is tuberculosis (TB). TB is a infectious disease which continues to kill 1·4 million people annually, striking severly Africa and Asia. Caused by a bacillus called Mycobacterium tuberculosis, one gets infected when the bacteria is transmitted from an ill person while talking, singing, coughing or sneezing. Once infected, the disease can remain silent for years, but suddenly to cause severe symptomatology and even death without treatment.
We have discovered that with the induction of an specific balanced immune response, the exaggerated inflammatory response triggered by the body against the bacilli can be modulated, and the development of TB avoided. This can be generated by “educating” the immunity of the host to not consider the bacilli as a danger, but as a food. With this purpose, we have developed Nyaditum resae ® (NR), to be given in low doses daily for short periods of time (2 weeks) and able to generate this balanced immune response.

It's a nutraceutical with natural origin, a low-cost production, well-tolerated and safe. For being a probiotic, NR is not submitted to the regulatory restrictions of drugs and is already available in the market.
Of oral administration, several available marketed forms and low price, NR is easy to be distributed and can be included in massive health interventions.

Nyaditum resae ® (NR) is the product able to induce the balanced immune response that diminish the risk of acquiring TB. Its production is based in the elaboration of a heat-killed culture of and environmental micobacteria belonging to the family of Mycobacterium fortuitum complex (new species: Mycobacterium manresensis). The final active ingredient is a powder in which a known concentration of a low dose heat-killed bacteria plus and excipient, and can be distributed in different final forms. After giving it daily for 14 days, it has been demonstrated that is able to stop the progression towards ac